Navigation Links
Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial

SAN DIEGO, Feb. 21 /PRNewswire/ -- Accumetrics, Inc. a privately-held medical device company and maker of the VerifyNow(R) family of tests that measure patient response to antiplatelet drugs, announced today that it has raised $28.8 million in its Series D financing. The syndicate was led by Arnerich Massena & Associates, Inc. and BBT Fund, L.P. Also participating in the round were previous investors: Essex Woodland Health Ventures, RiverVest, PTV Sciences, KB Partners and Kaiser Permanente Ventures.

"We feel Accumetrics will play a major role in personalized medicine by reducing the risk of cardiovascular disease and improving patient well-being. The company is late stage; they have a patented technology platform, multiple reimbursed and FDA cleared products that provide useful information to assist physicians in their care of patients regarding antiplatelet medications. This financing also supports a major clinical trial to link individualized therapy to improved clinical outcomes," said Anthony Arnerich, President and CEO, Arnerich Massena and Associates, Inc.

Because millions of patients are prescribed Plavix(R) and aspirin to lower the risk of coronary heart disease worldwide, the need to tailor antiplatelet therapy and improve clinical outcome is significant. Under the direction of the Scripps Advanced Clinical Trials center, Accumetrics is sponsoring a 6000 patient, multi-center trial, called GRAVITAS (Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety) to establish platelet function testing with VerifyNow as the standard of care. The Executive Committee comprises a group of nationally recognized physicians in the field of cardiology and includes Matthew Price, MD (Principal Investigator), Eric Topol, MD, Paul Teirstein, MD, and Christopher Cannon, MD.

"The GRAVITAS trial, using VerifyNow to gauge patients' response is prototypic of the future of individualized medicine," said Matthew Price, MD, Director, Cardiac Catheterization Laboratory, Scripps Clinic, La Jolla, California. "Not everyone responds the same way to current anti-platelet medications, so why should we treat our patients as if they did? The results of this trial will help physicians make clinical decisions to maximize safety and improve outcomes for a large number of patients taking anti-platelet therapy."

"Completion of this $28.8 million financing enables us to initiate the GRAVITAS study and positions the company for commercial success," said Steven Frankel, CEO. "This financing is recognition of the steady progress we've made focusing on surgical procedures where platelet function testing has immediate clinical relevance and gives us an excellent foundation in the hospital setting. We believe the results of the GRAVITAS trial will establish the VerifyNow system as a routine diagnostic tool."

About Accumetrics (

Accumetrics is committed to advancing medical understanding of platelets and enhancing quality of care for patients at a risk of cardiovascular disease by providing industry-leading diagnostic tests for platelet function assessment.

VerifyNow is the first, simple and accurate system for measuring the individual response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix(R), ReoPro(R), and Integrilin(R), the VerifyNow system provides a valuable tool to help guide treatment decisions.

CONTACT: Steven Frankel, 858-404-8201,

SOURCE Accumetrics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
3. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
4. Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin
5. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
6. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
7. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
8. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
11. Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology
Post Your Comments:
(Date:6/26/2016)... Story Highlights: ... the health care industry is causing providers to review ... Deloitte offers a suite of solutions for health care ... cost optimization: labor resource analysis, revenue cycle optimization and ... outcomes and better economics ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
Breaking Medicine Technology:
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
Breaking Medicine News(10 mins):